Born to survive: how cancer cells resist CAR T cell therapy
Jean Lemoine(Hospital of the University of Pennsylvania), Roch Houot(Inserm)
Cited by 121
Related Papers
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
|Blood|2022|80
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
|Blood Advances|2021|51
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
|Cancer Cell|2025|47